Protagonist Therapeutics, Inc. (PTGX)
Stock Price:
$18.03 USD
0.07 (0.36%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $15.06 -2.97 (-16.45%) Aug 10, 5:36 PM
Key Info
| Market Cap |
620.69M |
| Revenue (ttm) |
16.72M |
| Net Income (ttm) |
-73.41M |
| Shares Out |
35.67M |
| EPS (ttm) |
-2.55 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$18.03 |
| Previous Close |
$17.96 |
| Change ($) |
0.07 |
| Change (%) |
0.36% |
| Day's Open |
18.00 |
| Day's Range |
17.68 - 18.16 |
| Day's Volume |
187,488 |
| 52-Week Range |
4.47 - 19.67 |
More Stats
| Market Cap |
620.69M |
| Enterprise Value |
418.62M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.67M |
| Float |
28.43M |
| EPS (basic) |
-2.54 |
| EPS (diluted) |
-2.55 |
| FCF / Share |
-2.01 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.32M |
| Short Ratio |
2.92 |
| Short % of Float |
4.45% |
| Beta |
1.28 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
37.11 |
| PB Ratio |
9.36 |
| Revenue |
16.72M |
| Operating Income |
-72.38M |
| Net Income |
-73.41M |
| Free Cash Flow |
-66.05M |
| Net Cash |
202.06M |
| Net Cash / Share |
5.87 |
| Gross Margin |
1.38% |
| Operating Margin |
-432.79% |
| Profit Margin |
-439.00% |
| FCF Margin |
-394.91% |
| ROA |
-24.25% |
| ROE |
-58.31% |
| ROIC |
-97.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$30.50*
(69.21% upside)
Low
27.0
Current: $18.03
High
37.0
Target: 30.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 0.23 | 30.93 | 20.06 | - | - | - |
| Revenue Growth | -99.25% | 54.14% | - | - | - | - |
| Gross Profit | 0.23 | 30.93 | 20.06 | - | - | - |
| Operating Income | -80.52 | -42.27 | -37.90 | -32.70 | -14.79 | -9.32 |
| Net Income | -77.19 | -38.92 | -36.96 | -37.74 | -14.93 | -11.22 |
| Shares Outstanding | 25.89 | 22.36 | 17.69 | 6.50 | 0.25 | 0.23 |
| Earnings Per Share | -2.98 | -1.74 | -2.09 | -5.80 | -59.32 | -49.38 |
| Operating Cash Flow | -41.53 | -49.95 | 3.87 | -29.97 | -14.39 | -7.74 |
| Capital Expenditures | -0.97 | -0.49 | -0.67 | -0.35 | -0.40 | -0.30 |
| Free Cash Flow | -42.49 | -50.43 | 3.21 | -30.32 | -14.78 | -8.04 |
| Cash & Equivalents | 133 | 129 | 144 | 77.61 | 11.93 | 0.00 |
| Total Debt | 17.01 | - | - | - | - | - |
| Net Cash / Debt | 116 | 129 | 144 | 77.61 | 11.93 | 0.00 |
| Assets | 155 | 139 | 164 | 93.99 | 14.85 | - |
| Liabilities | 74.95 | 26.96 | 43.10 | 6.44 | 5.25 | - |
| Book Value | 79.96 | 113 | 121 | 87.56 | -27.40 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Protagonist Therapeutics, Inc. |
| Country |
United States |
| Employees |
80 |
| CEO |
Dinesh V. Patel |
Stock Information
| Ticker Symbol |
PTGX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PTGX |
| IPO Date |
August 11, 2016 |
Description
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.